• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

byJessie WillisandTeddy Guo
May 18, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Cabotegravir was shown to be superior to TDF-FTC in preventing HIV infection in women.

2. Both drugs were well tolerated and had similar adverse effects; however, there was a greater incidence of injection site reactions in the cabotegravir group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: HIV pre-exposure prophylaxis (PrEP), including oral tenofovir diphosphate plus emtricitabine (TDF-FTC), is available across sub-Saharan Africa. Unfortunately, many factors can contribute to poor compliance which may reduce the efficacy of these drugs. This phase 3 drug study evaluated the efficacy of a long-acting injection, cabotegravir, compared to daily TDF-FTC. Participants were randomly assigned 1:1 and received sham-controls of the non-assigned drug. The HIV incidence in the cabotegravir group was significantly lower than the TDF-FTC group. The study also demonstrated through drug screening blood tests that in the TDF-FTC group, daily drug compliance was less than 50%. Adverse events were similar between the two groups, except injection site reactions which were more frequent in the cabotegravir group. Limitations of this study include the lack of monitoring for oral daily pill taking; however, this provided an interesting finding in of itself. This study provides promising evidence for a safe, long-acting PrEP which could be used as an alternative to daily oral medication.

Click to read the study in the Lancet

Relevant Reading: HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery

In-Depth [randomized controlled trial]: HPTN 084 is a phase 3, randomized HIV prevention drug superiority trial across seven countries in sub-Saharan Africa. Eligible female participants were aged 18-45, at risk of HIV infection based on a risk score, reported at least two episodes of vaginal intercourse in the past 30 days, and consented to a long-acting contraceptive method. 3224 patients were randomized 1:1 to either cabotegravir injection with TDF-FTC placebo pill or TDF-FTC pill with cabotegravir injection placebo. The median age of participants was 25 years. The initial treatment plan was 5 weeks orally of both drugs to confirm cabotegravir tolerability before injection formulation. The injection was given at weeks 5, 9, and every 8 weeks thereafter. The following tail phase was open-label oral TDF-FTC daily for 48 weeks.

RELATED REPORTS

Global mortality of neonates born preterm has decreased nearly 50 percent since 1990

Several factors influence health programs conducted in the African American Church

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

Participants were monitored and tested for HIV at each follow-up visit. The HIV incidence in the cabotegravir group (0.2 cases per 100 person-years [0.06-0.52]) was significantly lower than the TDF-FTC group (1.82 cases per 100 person-years [1.3-2.57]; hazard ratio 0.12, p<0.0001). A randomly selected 405 of the TDF-FTC group had tenofovir levels tested, 42.1% of blood samples demonstrated consistent daily use. Injection site reactions were more frequent in the cabotegravir group (38.0% vs. 10.7%) compared to placebo injection; however, they did not affect treatment.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Cabotegravirglobal healthHIVHIV/AIDShuman immunodeficiency virus (HIV)pre-exposure prophylaxis (PrEPTDF-FTCTenofovir
Previous Post

Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial

Next Post

#VisualAbstract: Increased physical activity is a long-term protective factor for dementia

RelatedReports

Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia
Chronic Disease

Global mortality of neonates born preterm has decreased nearly 50 percent since 1990

June 15, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent
StudyGraphics

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

April 14, 2022
RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time
Infectious Disease

Chlorfenapyr insecticidal nets provide strong protection against malaria in sub-Saharan Africa

April 6, 2022
Next Post
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia

#VisualAbstract: Increased physical activity is a long-term protective factor for dementia

Obstetric scoring systems overestimate cases of severe sepsis

High pediatric sequential organ failure assessment (pSOFA) score may predict hospital mortality in emergency department setting

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.